Infiniwell BPC-157 FAQ

It is a single-ingredient oral peptide capsule, 500 mcg of synthetic BPC-157, marketed for tissue repair and recovery. The two situations it lines up with best are stubborn musculoskeletal injuries (tendon, ligament, muscle) that haven't resolved with rehab, and upper-GI complaints like gastritis or NSAID-related stomach irritation — the gut use case fits the oral route best because BPC-157 was originally identified in gastric juice.

One active: 500 mcg of synthetic BPC-157 in a vegetarian capsule, with no filler stack and no proprietary blend. Infiniwell sells the peptide on its own rather than co-mingling glutamine, zinc carnosine, or other ingredients to pad the label. Confirm the exact amount on your current bottle, since the label is the authoritative source.

This is the key question. Almost all of the impressive animal research uses injected BPC-157 (subcutaneous or intraperitoneal). The oral capsule is a different delivery route. The most honest reading of the current data is that the oral form most likely acts locally in the GI tract — which fits the peptide's gastric origin — plus some systemic effect, but the systemic tendon-and-ligament case is the weakest part of the picture. If your goal is gut-related, the oral route is a better fit than if your goal is a far-off joint.

Labels typically suggest one to two capsules daily. A common approach for the gut use case is one capsule first thing in the morning, about 20 to 30 minutes before food, in a little water — the empty stomach gives the local effect a better shot. For a tendon or ligament project, two capsules a day (one in the morning, one between lunch and dinner), again on a relatively empty stomach. Pair it with the actual rehab; it is meant to push through a plateau, not replace loading the tissue.

Treat it as a time-limited experiment, not a daily staple — a common pattern is four to six weeks on, then two weeks off, tied to a specific project with a clear before-and-after. Running it indefinitely is not advisable: the long-term human data does not exist, the regulatory environment is uncertain, and a compound whose headline mechanism involves new blood-vessel growth is not one to stay on permanently without monitoring.

Firm stops: anyone with active or recent cancer (the angiogenesis mechanism is a theoretical risk), and anyone pregnant or breastfeeding (no data). Check with a prescriber first if you take immunosuppressants. It is also a poor fit for vague, un-worked-up complaints, and it should not be stacked with high-dose NSAIDs or oral steroids, whose mechanisms work against it.

It is not FDA-approved for any human indication, and it is not classified as a DSHEA dietary supplement. The status is actively shifting in 2026: BPC-157 came off the FDA's Category 2 list in April 2026 and is one of several peptides under review for the 503A compounding list in July 2026. Practically, legitimate access runs through the practitioner channel for the oral form and through physicians and compounding pharmacies for the injectable. Read the current rules and the label, and expect them to keep moving.

Honestly, this is the most debated point. The case for oral BPC-157 is the gastric-origin argument — a peptide that evolved in the gut may be absorbed and used there. The case against is that small peptides taken by mouth are largely broken down by stomach acid before they get far. The current data leans toward meaningful local GI effects plus some systemic effect, with the systemic story being the weaker part. That is why the oral form is a better bet for the gut use case than for a distant joint.

Yes — that is the single biggest predictor of whether people report anything. The users who got something useful out of BPC-157 were specific about what they were targeting and disciplined about combining it with physical therapy and tissue loading. The ones who took the capsule and went back to resting rarely reported a difference. Frame it as a six-week experiment bolted onto an active recovery plan, not a standalone cure.